RNS Number : 7254G Renalytix PLC 21 July 2023     Renalytix plc ("Renalytix" or the "Company")   Middle East Distribution Agreement with Vector Pharma   Commercial availability of kidneyintelX.dkd™ expanded to an estimated 4 million DKD Patients in the Middle East   Distribution agreement opens

RNS Number : 2648G Renalytix PLC 17 July 2023   The following amendment has been made to the ' Issue of Shares' announcement released on 17 July 2023 at 07:00 under RNS No 1495G   The correct figure for the principal remaining under the convertible bond   after the settlement of the repayment is

RNS Number : 1495G Renalytix PLC 17 July 2023   Renalytix plc ("Renalytix" or the "Company")   Issue of Shares   LONDON and SALT LAKE CITY -   July 17, 2023 -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX) , announces the repayment of $1.06 million of the Company's convertible bond, further details

RNS Number : 2729F Renalytix PLC 07 July 2023     Renalytix plc ("Renalytix" or the "Company")   Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions 12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that

RNS Number : 2612F Renalytix PLC 06 July 2023   Renalytix plc ("Renalytix" or the "Company")   Grant of Share Options   LONDON and SALT LAKE CITY -   July 6, 2023 -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled

RNS Number : 7155E Renalytix PLC 03 July 2023       Renalytix plc ("Renalytix" or the "Company")   Directorate Change Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors   LONDON and SALT LAKE CITY -   July 3, 2023 -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX), the

RNS Number : 5264E Renalytix PLC 30 June 2023       THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.   Renalytix plc ("Renalytix" or the "Company")   FDA Approves KidneyIntelX.dkd™   FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline

RNS Number : 7716C Renalytix PLC 15 June 2023     Renalytix plc ("Renalytix" or the "Company")   KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences Four new data presentations, including late breaking clinical study data,

RNS Number : 1817C Renalytix PLC 09 June 2023     Renalytix plc ("Renalytix" or the "Company")   Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023   LONDON and SALT LAKE CITY , June 9, 2023   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in

RNS Number : 1562C Renalytix PLC 08 June 2023       Renalytix plc    ("Renalytix" or the "Company")   Result of General Meeting   LONDON and SALT LAKE CITY , June 8, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at the General Meeting (" GM ") held earlier today all resolutions